On this page
What is Hyperthyroidism?
The thyroid is a small, butterfly-shaped gland located at the front of the neck, just below the Adam’s apple. Despite its modest size, it plays a pivotal role in regulating a vast array of bodily functions by producing hormones that control:
- How efficiently the body uses energy (metabolism)
- The body’s consumption of oxygen
- Heat production and body temperature regulation
- Heart rate, digestion, muscle function, and brain development
Thyroid disorders generally arise when this gland produces too many or too few hormones. An overactive or underactive thyroid can therefore trigger a wide range of health problems affecting virtually every organ system.
The term hyperthyroidism is a condition in which there is an excess of thyroid hormones in the body. In other words, the gland is overactive. It works too hard, causing an abnormal acceleration of many physiological processes, such as metabolism and heart rate.
The main symptoms with which hyperthyroidism presents can vary considerably from one patient to another, but typically include:
- Anxiety, nervousness, and irritability
- Mood swings and emotional instability
- Fatigue or muscle weakness
- Heat intolerance
- Sleep disturbances
- Hand tremors
- Rapid and/or irregular heart rate
- Diarrhea
- Unexplained weight loss
- Goiter (visible swelling at the front of the neck)
If left untreated or poorly managed, hyperthyroidism can lead to serious and sometimes irreversible complications affecting the:
- Heart (arrhythmias, heart failure)
- Bones (osteoporosis and increased fracture risk)
- Muscles (proximal myopathy)
- Menstrual cycle and fertility
During pregnancy, maintaining thyroid hormone levels within the normal range is especially critical, as deviations can endanger both the mother and the developing baby.
Causes
Thyroid overactivity is defined as an excessive, unregulated production of two key thyroid hormones:
- Triiodothyronine (T3)
- Thyroxine (T4)
The rise in circulating T3 and T4 levels triggers a negative feedback response: it suppresses the pituitary gland’s output of TSH (thyroid-stimulating hormone). A low or undetectable TSH level is therefore often the first laboratory clue pointing toward hyperthyroidism and is the most useful initial blood test in clinical practice.
There are several distinct conditions that can cause the thyroid to become overactive. The most important are described below.
Autoimmune Hyperthyroidism (Graves’ Disease)
In approximately three out of four cases, an overactive thyroid is caused by Graves’ disease (also known as Basedow-Graves disease). This is an autoimmune disorder, a condition where the immune system mistakenly attacks the body’s own tissues. In Graves’ disease, the immune system produces abnormal antibodies called TRAb (TSH receptor antibodies) that bind to and continuously stimulate TSH receptors on the thyroid, driving it to produce excessive amounts of hormone regardless of the body’s actual needs.
The exact cause of Graves’ disease remains unknown, but several risk factors have been identified:
- Sex and age: It predominantly affects women, especially those between 20 and 50 years of age
- Family history: A significant genetic predisposition exists
- Smoking: Cigarette smoking is a major and avoidable risk factor, especially for the eye complications of the disease
Beyond the classic features of hyperthyroidism, Graves’ disease causes a distinctive eye condition called Graves’ ophthalmopathy (thyroid eye disease): inflammatory changes affect the soft tissues and muscles behind the eyes, causing them to be pushed forward (exophthalmos or proptosis). This can result in a wide-eyed, staring appearance and may cause eye discomfort, double vision, or even vision loss in severe cases.
The main therapeutic approaches for Graves’ disease are:
- Antithyroid medications
- Surgery
- Radioactive iodine therapy
Thyroid Nodules
Less commonly, hyperthyroidism can arise when nodules develop within the thyroid gland. These nodules are usually benign (non-cancerous) growths that contain functional thyroid tissue. This tissue can produce hormones independently, without the normal regulatory signal from TSH. When one or more nodules produce excess hormone autonomously, the condition is called a toxic adenoma (single nodule) or toxic multinodular goiter (multiple nodules).
The precise reason why some people develop thyroid nodules is not fully understood, but they are significantly more common in individuals over 60 years of age and in those with long-standing iodine deficiency.
Medications
An increase in iodine intake can prompt the thyroid to produce more hormone than the body requires. This can occur when certain iodine-containing medications are taken. A key example is amiodarone, a drug widely used to treat specific types of cardiac arrhythmia that contains about 37% iodine by weight.
Drug-induced hyperthyroidism usually improves once the offending medication is discontinued, though normalization of thyroid function may take several months.
Other Causes
Additional, less common causes of hyperthyroidism include:
-
Elevated beta-hCG (human chorionic gonadotropin): This pregnancy hormone structurally resembles TSH and can weakly stimulate the thyroid. Transient hyperthyroidism of pregnancy may occur in early pregnancy, multiple pregnancies, or molar pregnancy
-
Pituitary adenoma: A rare benign tumor of the pituitary gland that secretes excess TSH, inappropriately driving thyroid hormone production
-
Thyroiditis: Inflammation of the thyroid gland (from autoimmune, post-viral, or postpartum causes) can cause a temporary release of stored hormones, producing a transient hyperthyroid phase
-
Thyroid cancer: In rare cases, a functioning thyroid carcinoma can produce excess hormone
Symptoms
Thyroid hormones serve as the body’s primary regulators of metabolic rate. Together, these processes are known as metabolism. When thyroid hormones are produced in excess, virtually every bodily function tends to accelerate.
The resulting symptoms are numerous. They can appear gradually or suddenly, may be mild or severe, and, most importantly, can differ substantially from one patient to another. This variability often makes early diagnosis challenging, as patients may initially attribute their symptoms to stress or aging.
Common symptoms of hyperthyroidism include:
- Nervousness and irritability
- Emotional lability, which includes mood swings, anxiety, or even depression, may occur
- Warm, moist skin and excessive sweating
- Hyperactivity: difficulty relaxing or feeling driven by an internal restless energy
- Palpitations and tachycardia: when the heart beats faster and sometimes irregularly
- Fine tremor of the hands
- Anxiety
- Heat intolerance: feeling uncomfortably warm in normal or cool environments
- Insomnia and sleep difficulties
- Weight loss despite a normal or increased appetite
- Brittle hair and weakened nails
- Muscle weakness, particularly in the upper arms and thighs (proximal myopathy)
- Increased bowel frequency, though frank diarrhea is uncommon
- Frequent urination and excessive thirst
- Itching and/or urticaria
- Muscle spasms or tremors
- Palmar erythema (reddening of the palms)
- Reduced libido
- Menstrual irregularities in women: lighter periods or oligomenorrhea
In many patients, symptoms are initially mistakenly attributed to general nervousness or stress. This can delay diagnosis by months. If you recognize several of these symptoms occurring together, consult your doctor promptly.
In Graves’ disease specifically, the eyes may appear enlarged or protruding (exophthalmos) due to inflammation and swelling of the orbital tissues.
Some patients also develop a visible swelling at the front of the neck because the thyroid gland becomes enlarged. This condition is known as a goiter.
Diagnosis
The diagnosis of hyperthyroidism follows a well-established clinical protocol. This process aims not only to confirm hormone excess but also to identify its precise underlying cause, which is an essential step for selecting the most appropriate treatment.
Physical Examination and Medical History
The diagnostic process begins with a thorough medical history and physical examination. The clinician looks for characteristic signs including:
- Elevated resting heart rate
- Fine finger tremors visible at rest
- Brisk (hyperreflexic) deep tendon reflexes
- Eye changes, such as exophthalmos, lid lag, or stare
- Neck palpation: This is done to detect an enlarged thyroid, known as goiter, or the presence of discrete nodules.
- Skin assessment: warm, moist skin; palmar erythema.
A detailed medical history, including family history of thyroid disease and current medications, is equally important.
Laboratory Tests
Blood tests are the cornerstone of biochemical confirmation. Key tests include:
-
TSH (thyroid-stimulating hormone): The most sensitive screening test. In primary hyperthyroidism, TSH is typically very low or undetectable, because the excess of circulating thyroid hormones suppresses pituitary TSH secretion via negative feedback.
-
Free T4 (FT4) and Free T3 (FT3): These values are typically elevated in hyperthyroidism. In some patients, a condition called “T3 toxicosis” may occur, in which only FT3 is elevated while FT4 remains normal.
-
TRAb (TSH receptor antibodies): Elevated TRAb levels confirm the diagnosis of Graves’ disease and distinguish it from other causes.
-
Anti-TPO and anti-thyroglobulin antibodies: While less specific for hyperthyroidism, elevated levels may suggest an underlying autoimmune thyroiditis.
Imaging and Instrumental Diagnostics
To characterize the morphology and functional activity of the thyroid gland, the following studies may be requested:
-
Thyroid ultrasound with Color Doppler: Evaluates gland size, echogenicity, nodule characteristics, and vascularity. In Graves’ disease, blood flow within the gland is markedly increased (the so-called “thyroid inferno” pattern).
-
Thyroid scintigraphy (radionuclide scan): A functional imaging study using a small amount of radioactive tracer (technetium-99m or radioactive iodine) to map the gland’s activity. This is essential for distinguishing between:
- Diffuse toxic goiter (Graves’ disease): uniform, increased uptake throughout the gland
- Toxic adenoma (Plummer’s disease): a single “hot” nodule that suppresses the surrounding gland
- Toxic multinodular goiter: multiple areas of increased uptake
- Thyroiditis: Tracer uptake is markedly reduced or absent, since hormone release comes from stored hormone rather than newly produced hormone
Treatment
The primary goal of treatment is to restore euthyroidism, or normal thyroid hormone levels. This helps relieve symptoms and prevents long-term cardiovascular and skeletal complications. Treatment is individualized based on the patient’s age, the severity and cause of hyperthyroidism, reproductive plans, and comorbidities.
Antithyroid Drug Therapy
Antithyroid medications (also called thionamides or thyreostatics) are often the initial treatment of choice, particularly for Graves’ disease. The two main agents are:
-
Methimazole (Tapazole): The preferred drug in most patients outside of early pregnancy. It is highly effective, can be given as a single daily dose, and has a favorable side-effect profile. It works by blocking the enzyme thyroid peroxidase, thereby inhibiting the synthesis of new thyroid hormones.
-
Propylthiouracil (PTU): Used less frequently due to a risk of serious liver toxicity, but it remains the drug of choice during the first trimester of pregnancy and in the management of thyroid storm (a life-threatening thyroid emergency), as it also blocks peripheral conversion of T4 to the more potent T3.
Important points about antithyroid drugs:
- They do not cure the underlying autoimmune process. Instead, they suppress hormone production while the immune system is allowed to, hopefully, settle.
- In Graves’ disease, a treatment course of 12–18 months leads to sustained remission in approximately 30–50% of patients
- Common side effects include rash and itching; rare but serious side effects include agranulocytosis (dangerous drop in white blood cells) and liver toxicity.
Radioactive Iodine
Radioactive iodine (RAI, or I-131) therapy is one of the most commonly used definitive treatments for hyperthyroidism, particularly in adults with Graves’ disease or toxic nodular goiter. It is administered as a simple oral capsule or liquid.
The thyroid gland selectively absorbs iodine (both radioactive and non-radioactive), so the I-131 concentrates within thyroid cells and emits radiation that gradually destroys the overactive thyroid tissue over several weeks to months.
Key considerations:
- Highly effective: most patients achieve euthyroidism or become hypothyroid after one dose.
- The majority of treated patients will develop hypothyroidism over time, which is then easily managed with daily levothyroxine replacement therapy
- Contraindicated in pregnancy and breastfeeding
- Should be used with caution in active, severe Graves’ ophthalmopathy, as it may temporarily worsen eye disease
- Patients are advised to follow radiation safety precautions for a period after treatment
Surgical Treatment (Thyroidectomy)
Surgical removal of part or all of the thyroid gland (partial or total thyroidectomy) is indicated in specific clinical scenarios:
- Large goiter causing compressive symptoms (difficulty swallowing, breathing, or a sensation of pressure in the neck).
- Suspected concurrent thyroid cancer.
- Women planning pregnancy in the near future who cannot wait for antithyroid drugs or radioiodine to take effect.
- Active, severe Graves’ ophthalmopathy: In these patients, surgery may be preferred over radioiodine to avoid worsening of eye disease.
- Patient preference for a definitive, one-time procedure.
Total thyroidectomy will result in permanent hypothyroidism requiring lifelong levothyroxine replacement. Potential surgical risks include damage to the parathyroid glands (causing low calcium) and injury to the recurrent laryngeal nerve (causing voice changes).
Symptomatic Therapy with Beta-Blockers
While awaiting the effects of definitive treatments, beta-blockers (such as propranolol, atenolol, or metoprolol) play an important supportive role. They do not reduce thyroid hormone levels, but they rapidly alleviate the peripheral symptoms driven by excess hormone:
- Palpitations and tachycardia
- Tremors
- Anxiety
- Heat intolerance and sweating
They are particularly valuable in the acute phase of treatment and are considered essential in the management of thyroid storm.
Lifestyle and Nutritional Support
Clinical treatment should be complemented by targeted lifestyle measures:
-
Iodine management: Patients with autoimmune thyroid disease should avoid excessive iodine intake from sources such as seaweed, iodine-rich supplements, and iodinated contrast agents, as excess iodine can worsen hyperthyroidism.
-
Stop smoking: In Graves’ disease, smoking is the single most important modifiable risk factor for the development and worsening of ophthalmopathy. All patients should be strongly advised and supported to quit.
-
Bone health: Hyperthyroidism accelerates bone turnover and can lead to reduced bone density and osteoporosis over time. Ensuring adequate dietary intake of calcium and vitamin D is important; supplementation may be warranted if dietary intake is insufficient.
-
Stress management: While stress is not a direct cause of hyperthyroidism, psychophysical stress may trigger or worsen autoimmune flares. Mindfulness techniques, regular moderate exercise, and adequate sleep are beneficial.
-
Regular monitoring: Thyroid hormone levels should be checked regularly (typically every 4–6 weeks during dose adjustment, then every 3–6 months once stable) to guide treatment decisions.
Hyperthyroidism During Pregnancy
Thyroid disorders during pregnancy require particular vigilance, as both the mother and the fetus can be affected. Hyperthyroidism should be suspected during pregnancy when the following signs and symptoms are present:
- Warm, moist skin
- Weight loss or failure to gain weight appropriately
- Heart rate consistently above 100 bpm
- Visible goiter
- Muscle weakness
- Excessive sweating
- Heat intolerance
- Generalized fatigue
- Anxiety
The diagnosis is confirmed through laboratory testing, specifically by measuring FT4, FT3, and TSH. The following pattern indicates hyperthyroidism:
- Elevated FT4
- Elevated FT3
- Low or suppressed TSH
Note: In the first trimester of normal pregnancy, TSH levels naturally fall and FT4 may transiently rise due to the stimulatory effect of hCG on the thyroid. Careful interpretation by an experienced clinician is essential to distinguish physiological changes from true pathological hyperthyroidism.
Maternal Complications of Untreated Hyperthyroidism in Pregnancy
Failure to treat thyrotoxicosis during pregnancy can lead to serious maternal complications:
- Hypertension
- Preterm labor
- Preeclampsia
- Cardiac complications (heart failure, arrhythmias)
- Placental abruption
- Miscarriage
- Anemia
Fetal and Neonatal Complications
- Low birth weight
- Prematurity
- Intrauterine fetal death or neonatal death
- Congenital malformations
- Fetal or neonatal hyperthyroidism: TRAb antibodies can cross the placenta and stimulate the fetal thyroid, causing fetal or neonatal Graves’ disease
Management During Pregnancy
Hyperthyroidism in pregnancy can be effectively controlled with antithyroid drug therapy:
- PTU is preferred in the first trimester due to concerns about methimazole-associated embryopathy (rare congenital defects). After the first trimester, methimazole is generally considered acceptable.
- The lowest effective dose should always be used to avoid fetal hypothyroidism
- Common side effects are mild (rash, itching); serious events (agranulocytosis, hepatotoxicity) are rare but require monitoring
- Surgery is reserved for exceptional cases, such as suspected malignancy or severe drug intolerance, typically performed in the second trimester
- Laboratory tests (FT4, FT3, TSH) should be repeated every 4 weeks throughout the entire pregnancy to guide dose adjustments
Breastfeeding
Both methimazole and PTU are compatible with breastfeeding and are not contraindicated during lactation. As a precaution, it is advisable for the nursing mother to take the medication in divided doses, timed away from breastfeeding sessions. Periodic thyroid function monitoring of the infant is also recommended.
The maternal and fetal prognosis of these pregnancies is excellent when hyperthyroidism is adequately controlled.
Graves’ Disease and Pregnancy
Pre-existing Graves’ disease is significantly influenced by the immunological changes of pregnancy. The immune tolerance that develops during gestation tends to attenuate autoimmune activity, and many women with Graves’ disease experience spontaneous improvement or remission during pregnancy. This is especially true in the second and third trimesters. However, a postpartum flare is common.
Medical management during pregnancy aims to achieve normal thyroid hormone levels using the minimum effective dose of antithyroid medication. Over-treatment and fetal hypothyroidism must be avoided, as adequate thyroid hormone levels are essential for normal fetal brain development.
Before attempting to conceive, women with Graves’ disease should ideally achieve a stable euthyroid state. This can be accomplished through:
- Prolonged antithyroid drug therapy with confirmed remission.
- Definitive treatment (surgery or radioactive iodine) should be completed well in advance of conception. Note that pregnancy should be avoided for at least 6 months after radioactive iodine treatment.
Early and coordinated care from both an endocrinologist and an obstetrician is strongly recommended for all pregnant women with known or suspected Graves’ disease.
Sources and Bibliography
- NHS – Overactive thyroid (hyperthyroidism): Treatment (licensed under the Open Government Licence)
- American Thyroid Association – thyroid.org
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH) – Hyperthyroidism
- Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi:10.1089/thy.2016.0229
- Alexander EK, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389.
- Kahaly GJ, et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal. 2018;7(4):167–186.
